(CTXR) Citius Pharmaceuticals - Ratings and Ratios

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is a biopharmaceutical company specializing in the development and commercialization of critical care and oncology products. The companys lead approved product, LYMPHIR, is an FDA-cleared immunotherapy designed for the treatment of cutaneous T-cell lymphoma (CTCL). Its late-stage pipeline includes Mino-Lok, an antibiotic lock solution currently in Phase 3 trials for the salvage of infected central venous catheters in patients with catheter-related bloodstream infections (CRBSIs), and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids, which has completed Phase 2b trials. The company was established in 2007 and operates from its headquarters in Cranford, New Jersey. For more information, visit https://citiuspharma.com.

Ticker Symbol: CTXR
Exchange: NASDAQ
Type: common stock
Country Origin: United States
GICS Sub Industry: Pharmaceuticals

Average Volume 20d: 87,107
Last Price: 1.79
SMA 20: 2.05
SMA 50: 2.80
SMA 200: 10.39
ATR: 0.27

Market Cap: $14.09M USD
P/E: 0.00
P/E Forward: 9.13
P/B: 0.22
P/S: 0.00
RoE: -60.66

3-Month Forecast:
Based on the analysis of and , CTXR is expected to experience continued volatility within the $1.50-$2.50 range. The stock is currently trading below its SMA 20 and SMA 50, indicating bearish momentum. However, the forward P/E of 9.13 suggests potential undervaluation. The negative RoE and low market cap highlight significant risks, but the completion of late-stage trials for Mino-Lok and CITI-002 could act as catalysts for upside movement. ATR of 0.27 indicates moderate price fluctuations.